Moving forward, Dr. Fichtenbaum said it will ... questions if we want to have better outcomes for patients regarding cytokine storms: Who is at most risk, and is there a way we can predict a ...

Numerous additional cytokines are under investigation at the preclinical stage, including IL-12–IL-23, IL-17 and IL-18. As therapeutic goals move from disease control towards remission induction ...

A cytokine networking theory for the cause of ... prompted the field to move in another direction. Researchers began to think about innate immunity contributing to an inappropriate local tissue ...

Analyst Andres Y. Maldonado of H.C. Wainwright maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report), retaining the price target of $15.00. Don't Miss our Black Friday Offers: ...